XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.3
Basis of Presentation (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Product Information [Line Items]        
Revenue from related parties $ 3,917,597 $ 11,140,652 $ 13,795,063 $ 17,119,485
Convertible Notes Payable [Member]        
Product Information [Line Items]        
Antidilutive securities excluded from computation of earnings per share, amount     97,166,963 773,269
Stock options and vesting or unissued stock awards granted to employees [Member]        
Product Information [Line Items]        
Antidilutive securities excluded from computation of earnings per share, amount     2,350,481 2,003,252
Stock options and vesting or unissued stock awards granted to board members and consultants [Member]        
Product Information [Line Items]        
Antidilutive securities excluded from computation of earnings per share, amount     1,707,939 572,948
Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Accounts receivable $ 5,591,156   $ 5,591,156  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Individual [Member]        
Product Information [Line Items]        
Concentration risk, percentage     42.00%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]        
Product Information [Line Items]        
Concentration risk, percentage       99.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]        
Product Information [Line Items]        
Concentration risk, percentage       99.00%